# Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects

> **NCT01665924** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG0634 100mg capsule once a day for 10 days

## Key facts

- **NCT ID:** NCT01665924
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2012-09
- **Final completion:** 2012-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01665924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01665924, "Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01665924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*